📊 SLS Key Takeaways
Is SELLAS Life Sciences Group, Inc. (SLS) a Good Investment?
SELLAS Life Sciences faces severe operational distress with revenue collapsed to $79K (-100% YoY) and substantial operating losses of $9.3M, indicating critical pipeline or commercialization failures typical of troubled biotech firms. While the company maintains a strong balance sheet with $107M cash and zero debt, operating cash burn of $8.8M annually combined with minimal revenue generation creates an unsustainable business model requiring significant clinical or commercial breakthroughs to avoid extended dilution.
SELLAS Life Sciences Group, Inc. Key Strengths (SLS)
- Fortress balance sheet with $107.1M cash and zero long-term debt
- Exceptional liquidity position (17.22x current ratio) providing 12+ years of cash runway at current burn rate
- Minimal capital expenditure requirements ($6K) indicating lean operations
SLS Stock Risks: SELLAS Life Sciences Group, Inc. Investment Risks
- Near-total revenue collapse (-100% YoY to $79K) suggesting failed commercialization or major pipeline setbacks
- Sustained operating cash burn of $8.8M annually with negative free cash flow
- Complete absence of insider buying activity despite potential deep valuation, indicating management lacks confidence in recovery
- As pharmaceutical company, revenue collapse suggests failed clinical trials or severe regulatory/market challenges
Key Metrics to Watch
- Quarterly revenue trend and pipeline advancement announcements
- Operating cash burn rate trajectory
- Clinical trial progress and FDA communications
- Cash runway sufficiency given revised operating plan
SELLAS Life Sciences Group, Inc. (SLS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.22x current ratio provides a solid financial cushion.
SLS Profit Margin, ROE & Profitability Analysis
SLS vs Healthcare Sector: How SELLAS Life Sciences Group, Inc. Compares
How SELLAS Life Sciences Group, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is SELLAS Life Sciences Group, Inc. Stock Overvalued? SLS Valuation Analysis 2026
Based on fundamental analysis, SELLAS Life Sciences Group, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
SELLAS Life Sciences Group, Inc. Balance Sheet: SLS Debt, Cash & Liquidity
SLS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: SELLAS Life Sciences Group, Inc.'s revenue has declined by 47% over the 5-year period, indicating business contraction. The most recent EPS of $-0.50 indicates the company is currently unprofitable.
SLS Revenue Growth, EPS Growth & YoY Performance
SLS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$7.0M | $-0.33 |
| Q2 2023 | N/A | -$8.4M | $-0.31 |
| Q1 2023 | N/A | -$11.1M | $-0.47 |
| Q3 2022 | N/A | -$7.0M | $-0.34 |
| Q2 2022 | N/A | -$4.6M | $-0.30 |
| Q1 2022 | $1.0M | -$2.4M | $-0.16 |
| Q3 2021 | N/A | -$4.5M | $-0.45 |
| Q2 2021 | N/A | -$4.4M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
SELLAS Life Sciences Group, Inc. Dividends, Buybacks & Capital Allocation
SLS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for SELLAS Life Sciences Group, Inc. (CIK: 0001390478)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SLS
What is the AI rating for SLS?
SELLAS Life Sciences Group, Inc. (SLS) has an AI grade of C with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SLS's key strengths?
Claude: Fortress balance sheet with $107.1M cash and zero long-term debt. Exceptional liquidity position (17.22x current ratio) providing 12+ years of cash runway at current burn rate.
What are the risks of investing in SLS?
Claude: Near-total revenue collapse (-100% YoY to $79K) suggesting failed commercialization or major pipeline setbacks. Sustained operating cash burn of $8.8M annually with negative free cash flow.
What is SLS's revenue and growth?
SELLAS Life Sciences Group, Inc. reported revenue of $79.0K.
Does SLS pay dividends?
SELLAS Life Sciences Group, Inc. does not currently pay dividends.
Where can I find SLS SEC filings?
Official SEC filings for SELLAS Life Sciences Group, Inc. (CIK: 0001390478) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SLS's EPS?
SELLAS Life Sciences Group, Inc. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SLS's fundamental grade?
Based on our AI fundamental analysis in May 2026, SELLAS Life Sciences Group, Inc. has a C grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SLS stock overvalued or undervalued?
Valuation metrics for SLS: ROE of -7.8% (sector avg: 15%), net margin of -10,641.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SLS's AI grade for 2026?
Our dual AI analysis gives SELLAS Life Sciences Group, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SLS's free cash flow?
SELLAS Life Sciences Group, Inc.'s operating cash flow is $-8.8M, with capital expenditures of $6.0K. FCF margin is -11,205.1%.
How does SLS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,641.8% (avg: 12%), ROE -7.8% (avg: 15%), current ratio 17.22 (avg: 2).